Day T A, Bennett J L, Pax R A
Department of Pharmacology and Toxicology, Michigan State University, East Lansing, USA.
Parasitol Today. 1992 Oct;8(10):342-4. doi: 10.1016/0169-4758(92)90070-i.
Praziquantel (PZQ), a pyrazinoisoquinoline, was introduced as a novel anthelmintic in 1975. PZQ is currently the drug of choice for the treatment of a wide range of both veterinary and human trematode and cestode infections, including human schistosomiasis. Current estimates suggest that 150 million humans are infected with schistosomes, and it is expected that PZQ will play the lead role in chemotherapeutic control of those infections. Despite the time that has passed since its introduction and its obvious importance in global health care, it is not yet understood why PZQ is so selective and effective. The target molecules for PZQ have not been defined, nor are the sites of its effects within the parasites known. Here, Tim Day, James Bennett and Ralph Pax summarize some of the progress that has been made toward reaching these objectives in recent years.
吡喹酮（PZQ）是一种吡嗪异喹啉，于1975年作为一种新型驱虫药被引入。目前，吡喹酮是治疗多种兽医和人类吸虫及绦虫感染（包括人类血吸虫病）的首选药物。目前的估计表明，有1.5亿人感染了血吸虫，预计吡喹酮将在这些感染的化疗控制中发挥主导作用。尽管自其引入以来已经过去了很长时间，并且它在全球医疗保健中具有明显的重要性，但仍不清楚为什么吡喹酮如此具有选择性和有效性。吡喹酮的靶分子尚未确定，其在寄生虫体内的作用位点也不为人所知。在此，蒂姆·戴、詹姆斯·贝内特和拉尔夫·帕克斯总结了近年来在实现这些目标方面取得的一些进展。
